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Abstract
Background: Recurrent loss of part of the long arm of chromosome 11 is a well established hallmark of
a subtype of aggressive neuroblastomas. Despite intensive mapping efforts to localize the culprit 11q
tumour suppressor gene, this search has been unsuccessful thus far as no sufficiently small critical region
could be delineated for selection of candidate genes.
Methods: To refine the critical region of 11q loss, the chromosome 11 status of 100 primary
neuroblastoma tumours and 29 cell lines was analyzed using a BAC array containing a chromosome 11
tiling path. For the genes mapping within our refined region of loss, meta-analysis on published
neuroblastoma mRNA gene expression datasets was performed for candidate gene selection. The DNA
methylation status of the resulting candidate gene was determined using re-expression experiments by
treatment of neuroblastoma cells with the demethylating agent 5-aza-2'-deoxycytidine and bisulphite
sequencing.
Results: Two small critical regions of loss within 11q23 at chromosomal band 11q23.1-q23.2 (1.79 Mb)
and 11q23.2-q23.3 (3.72 Mb) were identified. In a first step towards further selection of candidate
neuroblastoma tumour suppressor genes, we performed a meta-analysis on published expression profiles
of 692 neuroblastoma tumours. Integration of the resulting candidate gene list with expression data of
neuroblastoma progenitor cells pinpointed CADM1 as a compelling candidate gene. Meta-analysis indicated
that CADM1 expression has prognostic significance and differential expression for the gene was noted in
unfavourable neuroblastoma versus normal neuroblasts. Methylation analysis provided no evidence for a
two-hit mechanism in 11q deleted cell lines.
Conclusion: Our study puts CADM1 forward as a strong candidate neuroblastoma suppressor gene.
Further functional studies are warranted to elucidate the role of CADM1 in neuroblastoma development
and to investigate the possibility of CADM1 haploinsufficiency in neuroblastoma.
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Neuroblastoma (NB) is a rare but often highly aggressive
tumour in children. Despite intensive gene copy number
and mRNA expression studies thus far only two genes,
namely MYCN [1]and PHOX2B [2-4] have been found to
be directly implicated in NB development. In order to pro-
vide clues for more effective therapies, insights into the
molecular pathogenesis of this tumour are urgently
needed. Analyses of recurrent patterns of somatically
acquired DNA copy number alterations resulted in the
delineation of three major genetic subgroups with predic-
tive tumour behaviour (subtype 1, 2A and 2B), of which
subtype 2A NB represents an aggressive subgroup of met-
astatic NB [5,6] characterised by loss of 11q, gain of 17q
and a normal MYCN copy number status [6].
Deletion of the long arm of chromosome 11 is found in
15–22% of sporadic NB [5-10] and has also been
described in constitutional cases of NB [11,12], suggesting
the presence of one or more tumour suppressor gene(s)
on chromosome 11. Functional evidence for a NB tumour
suppressor gene at 11q came from microcell mediated
chromosome transfer (MMCT) experiments, in which
transfer of an intact chromosome 11 in a NB cell line with
11q loss resulted in a more differentiated phenotype [13].
Array comparative genomic hybridisation (array CGH)
analysis of these MMCT hybrids revealed 11q25 as a plau-
sible location for a NB differentiation gene [14]. Extensive
microsatellite heterozygosity mapping studies however
point at various critical regions of loss, located at 11q23.3
[7] and within the chromosomal region 11q14-11q23
[15]. Despite these mapping efforts, no genes with proven
tumour suppressor activity in NB have been identified
thus far.
In this study, we used an integrated approach combining
high resolution copy number profiling and gene expres-
sion meta-analysis. This approach identified CADM1 as a
strong candidate 11q tumour suppressor gene with prog-
nostic power, which possibly exerts its effect through
haplo-insufficiency.
Methods
Array CGH copy number profiling of NB patients and cell 
lines
A description of the primary NB tumour samples and NB
cell lines as well as the array CGH procedure is given in
Michels et al. [16]. Twenty-five additional tumour cases
were profiled for this study, including 4 stage 1, 3 stage 2,
6 stage 3, 9 stage 4 and 3 stage 4S tumours according to
the International Neuroblastoma Staging System [17].
The maximal size of the lost region is determined as the
distance between the two normal clones flanking the lost
clones. Detailed data for 75 tumours are published by
Michels et al. [16]. Detailed data for the 25 additionally
profiled tumour cases are available in Additional File 1.
Data for all tumours are also accessible from the webtool
arrayCGHbase [18,19]. Mapping data are based on
Ensembl v44.
Meta-analysis of published NB gene expression datasets
Expression data were collected from seven independent
gene expression studies in NB [20-26]. For each of the
individual expression studies Cox regression analysis
(enter method) was performed for each gene present in
the defined SROs using the SPSS 15 software, allowing to
pinpoint genes within our SROs having prognostic power.
Next, in four studies for which genomic data were availa-
ble [21,22,25,26], tumours were also classified according
to the three major NB subtypes: subtype 1 (characterised
by mainly numerical aberrations and not 11q loss or
MYCN amplification), 2A (characterised by 11q loss,
without MYCN amplification) or 2B (characterised by
MYCN amplification). Following this subclassification an
independent Kruskal-Wallis analysis was performed for
each of the four studies using the R software package with
multiple testing correction. Genes were considered to be
significant when a p-value < 0.5 was calculated (Addi-
tional file 2).
Following these analyses, an intersection was made
between genes that were prognostically significant (Cox
regression analysis) in more than three independent stud-
ies and genes which had subgroup discriminating power
in more than two independent studies (Kruskal-Wallis
analysis) to identify the strongest candidate genes (see
results and discussion).
mRNA expression analysis for CADM1 in cell lines 
untreated or treated with DAC
NB cells were plated at day 0 and treated 24 h later with 3
μM DAC during 3 days. The NB cell line panel consisted
of CHP-134, CHP-901, CHP-902R, CLB-GA, GI-C-IN,
IMR-32, LA-N-1, LA-N-2, N206, NBL-S, NGP, NLF, NMB,
SH-SY5Y, SH-SY5Y TrkA, SJNB-1, SJNB-8, SJNB-12, SK-N-
AS, SMS-KAN, SMS-KCNR and STA-NB-1.2. Cells were
harvested and RNA was extracted for real-time quantita-
tive PCR using the RNeasy Mini kit (Qiagen). Primers for
CADM1 and four stably expressed reference genes
(HPRT1, GAPDH, YWHAZ, HMBS) are available in the
public RTPrimerDB database [27-29] (gene (RTPrimerDB-
ID): HPRT1 (7), GAPDH (3), YWHAZ (7), HMBS (4) and
CADM1 (3770)). DNAse treatment and real-time PCR
analysis were performed as previously reported [30].
Bisulphite sequencing
A cell line panel was composed including CHP-134, CHP-
901, CLB-GA, GI-C-IN-1, LA-N-1, LA-N-5, NB-13, NB-19,
N206, NBL-S, NGP, NLF, SHEP, SJNB-1, SJNB-6, SJNB-8,
SJNB-10, SJNB-1.2, SK-N-AS, SKN-BE (1n), SK-N-BE (2c),Page 2 of 9
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STA-NB-9, STA-NB-10, STA-NB-1.2, TR-14 and UHG-NP.
Approximately 1 μg of DNA was modified with sodium
bisulphite using the EZ DNA Methylation Kit (Zymo
Research). The resulting modified DNA was used as a tem-
plate in a PCR reaction. Briefly, PCR reaction was carried
out in a 50 μl reaction containing 30 ng of bisulphite
modified DNA, 1× Platinum Taq PCR reaction buffer
(Invitrogen), 6 mM MgCl2, 200 μm of each dNTP, 1.25 U
Platinum Taq polymerase (Invitrogen) and 300 nm of
each primer. PCR cycling conditions were as follows: 4
min of initial denaturation at 93°C, followed by 40 cycles
of 30 s denaturation at 93°C, 50 s of annealing at 57°C
and 30 s of extension at 72°C, followed by a final exten-
sion step of 4 min at 72°C. Primers were developed using
Bisearch [31,32] and tested for specificity using our in
house developed methBLAST software [33] and are avail-
able in the public methPrimerDB database [33](ID 243).
The primers were designed to assess the methylation sta-
tus of 20 CpG sites situated upstream of the transcription
start 4 μl of PCR product was cloned into TOPO-TA vector
and transformed into E. coli TOP10F' cells (Invitrogen)
and 10 positive clones were randomly selected for direct
sequencing using universal M13 primers. As a control,
normal human genomic DNA and SssI methylase (New
England Biolabs) treated DNA were processed respectively
as a negative and a positive control for methylation after
bisulphite modification and evaluated for overall bisul-
phite conversion using sequencing. A 100% conversion
was reached (data not shown). Furthermore, we verified
for preferential amplification of unmethylated or methyl-
ated alleles through sequencing of artificial mixture sam-
ples from normal DNA and different concentrations of
methylated DNA. We could confirm no amplification bias
(data not shown).
Results and Discussion
In an attempt to more accurately map 11q losses and to
identify potential homozygous losses that were previously
missed using low resolution analyses, we performed high
resolution BAC array CGH copy number profiling on 100
primary NB tumours (16 stage 1, 12 stage 2, 21 stage 3, 40
stage 4 and 11 stage 4S tumours) and 29 cell lines using a
1 Mb BAC array supplemented with a chromosome 11q
tiling path (position 63–72 Mb (11q13) and 84–134 Mb
(11q14.1-qter)). Three patterns of chromosome 11 loss
could be observed. Twenty-four (24%) tumours showed
loss of the entire chromosome 11. These tumours con-
sisted of predominantly low stage tumours with an overall
pattern of numerical imbalances. In addition, also 3 cell
lines (10%) showed whole chromosome 11 loss. Seven-
teen tumours (17%) and 16 cell lines (55%) showed par-
tial 11q loss. Most deletions were large encompassing the
distal end of 11q, in keeping with data from literature [6-
10,15,34,35]. In cell lines CLB-GA, SMS-KAN, and NB-5,
small interstitial losses were detected (respectively mini-
mal 42.90, 30.84, and 4.76 Mb in size). To our knowledge
this is the first report of interstitial 11q loss in SMS-KAN
and NB-5 cell lines. No homozygous 11q losses were
observed.
Two common minimal regions of loss (shortest region of
overlap, SRO) at 11q23 could be delineated (Figure 1).
The telomeric SRO (SRO1, 3.54–3.72 Mb, 11q23.2-
q23.3) is delineated by the breakpoints in N206 (centro-
meric border) and SMS-KAN (telomeric border) and con-
tains 31 genes. More centromeric, a second SRO (SRO2,
1.65–1.79 Mb, 11q23.1-q23.2) is delineated by the break-
points in STA-NB3 (centromeric border) and NB-5 (telo-
meric border) and contains 12 genes. Recent evidence
indicates that also miRNAs can function as tumour sup-
pressor genes. According to the miRBase, [36,37] (August
2007, version 10.0) no miRNAs were however located
within the defined SROs. The finding that the most distal
SRO partially overlaps with the SRO defined by Guo et al.
[7] and both SROs are positioned within the critical
region defined by Maris et al. [15] validates our mapping
efforts. Nevertheless, it is important to note that SRO
mapping should always be interpreted with care as indi-
vidual observations can dramatically reduce the size or
location of the SRO. This is especially the case when
including cell line data, in which alterations could be
induced during culturing. In this respect, it should there-
fore be noted that NB cell lines have been proven to be
very stable over time and that, although rare, interstitial
11q loss has also been described in primary NB tumours
[6,7,15,38], further underscoring the relevance of our
defined SRO regions.
To prioritize potential NB 11q candidate genes within the
two critical regions, we performed a meta-analysis on
publicly available gene expression data of 692 tumours
from seven independent studies [20-26]. An overview of
the obtained results is given in Additional file 2. In a first
analysis we determined which genes in our SROs have
prognostic power using Cox regression analysis. In total,
24 genes were prognostically significant in one or more
studies (see Additional file 2), of which four (CADM1,
NCAM1, CD3E, ZNF259) were significant in three or
more studies. In the four studies for which DNA copy
number data were available, we determined in a second
analysis which genes could discriminate between the var-
ious NB subgroups (subtype 1, 2A, 2B) (Kruskal-Wallis
test). This multi-group analysis was specifically applied
instead of a binary comparison between 11q normal ver-
sus 11q deleted samples in order to avoid combining
tumours with a distinct biology and prognosis. Thirteen
genes had discriminative power, of which five were signif-
icant in at least two studies (CADM1, NCAM1, BACE1,
ZNF259, KIAA0999). Genes that were prognostic signifi-Page 3 of 9
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Array CGH copy number profiling of chromosome 11 in neuroblastomaFigure 1
Array CGH copy number profiling of chromosome 11 in neuroblastoma. Top. Alignment of array CGH profiles for 
17 primary tumours and 16 cell lines showing partial 11q loss. Copy number losses are indicated by black bars along the chro-
mosome 11q ideogram (cen= centromere, tel= telomere). The common regions of loss are marked by dotted bars (SRO 1: 
dashed line, 3.54–3.72 Mb and SRO2: dotted line, 1.65–1.79 Mb).Bottom. Detailed view of genes within the two putative 
SROs.
BMC Cancer 2008, 8:173 http://www.biomedcentral.com/1471-2407/8/173cant in more than three independent studies and had sub-
group discriminating power in more than two
independent studies were considered as strong candidate
genes (CADM1, NCAM1 and ZNF259).
ZNF259 is a zinc finger protein involved in normal cell
cycle progression [39]. ZNF259 has been suggested as a
modifier gene in spinal muscular atrophy [40], but no
direct link with carcinogenesis has been established thus
far. NCAM1 is a neural cell adhesion molecule with an
important role in tumour migration and metastasis. In a
rat model it was demonstrated that NCAM transfected gli-
oma cells show a decreased invasion compared to low
NCAM expressing control cells [41]. Similarly, loss of
NCAM in a transgenic mouse model of pancreatic β cell
carcinogenesis caused the formation of lymph node
metastasis, whereas NCAM overexpression prevented
tumour metastasis [42]. In several tumour types, includ-
ing colon carcinoma [43], gastrointestinal neoplasia [44]
and astrocytic tumours [45], downregulation of NCAM
expression and an associated poor survival has been
described. In chemoresistant NB cells an enhanced inva-
sive capacity was observed due to downregulation of
NCAM adhesion receptors [46]. CADM1 encodes a cellu-
lar adhesion molecule with a role in synaptic formation of
neural cells [47]. This gene, also known as IGSF4 (immu-
noglobulin superfamily, member 4) or TSLC1 (tumour
suppressor in lung cancer-1), is a bona fide tumour sup-
pressor gene in non-small lung cancer and was identified
by functional complementation of a frequently deleted
region in nude mice [48]. Reduced or lost expression has
been described in a variety of human cancers and in vivo
suppression of tumorigenesis after restoration of expres-
sion has been demonstrated in esophageal cancer, cervical
cancer and prostate cancer [49-52].
To select the most promising candidate gene within the
three remaining candidate genes, we integrated the gene
expression profile of normal NB precursor cells (see Addi-
tional file 2). The transcriptome information of these nor-
mal fetal neuroblasts represents a unique resource for
identifying genes contributing to NB development and
the malignant phenotype [21]. Remarkably CADM1 was
the only gene in our candidate list that was differentially
expressed in NB versus neuroblasts using the Rank Prod-
uct algorithm. A significantly lower expression of CADM1
was observed when comparing unfavourable NB to neu-
roblasts [21]. This is in agreement with the Kruskall-Wallis
data showing CADM1 downregulation in unfavourable
NB compared to favourable subtype 1 NB. Consequently,
we consider CADM1 to be a compelling candidate NB
tumour suppressor gene for further analysis.
In several cancer types, two-hit inactivation of CADM1
occurs by LOH and hypermethylation of the promoter
region, whereas CADM1 mutations are rare. Indeed, it was
shown that only two CADM1 sequence variants could be
picked up in a panel of 31 NB cell lines [53], while in a
study of 25 NB with proven CADM1 allelic loss no muta-
tions were found in the remaining allele [54]. Epigenetic
modification has been described for several genes in NB
[55,56]. To study if the remaining allele is subject to meth-
ylation and resulting epigenetic silencing, we measured
CADM1 mRNA expression in a panel of 22 NB cell lines
before and after exposure to the demethylating agent 5-
aza-2'-deoxycytidine (DAC). Four out of 13 cell lines with
loss at the CADM1 locus showed a more than two fold
upregulation of CADM1 mRNA expression after DAC
treatment. This was also the case for two of the nine cell
lines with normal CADM1 copy number. Representative
examples of mRNA expression before and after treatment
with DAC are given in Figure 2. As the maximal observed
expression upregulation was 4.4 fold in cell line CHP-134,
these data were inconclusive to predict the involvement of
methylation associated CADM1 silencing in NB. Conse-
quently, we performed bisulphite sequencing of twenty
promoter region CpG dinucleotides in a panel of 31 NB
cell lines (including the cell lines that were studied in the
DAC experiment). Note, that the investigated CpG sites
also cover the 93 bp consensus CpG region described by
Kuramochi et al. [48]. Methylation of all studied CpG sites
was identified in 12.5, 20 and 11% of analysed clones in
the cell lines NGP, SH-EP and SK-N-BE(2c). It should be
noted that NGP was also present in the panel of cell lines
treated with DAC, where a more than two fold upregula-
tion was observed after DAC treatment. However, in all
other cell lines only sporadic CpG methylation was
detected at low frequency (< 30%). Based on this evidence
and taken in account that cell lines typically show a higher
extent of CpG island methylation compared to primary
NB, epigenetic CADM1 inactivation probably does not
play a major role in NB. The latter could explain the
observed limited fold changes in the DAC re-expression
data.
While CADM1 forms an excellent positional and func-
tional candidate tumour suppressor gene for NB, we can
not exclude a role for the 2 other identified candidates
suppressor genes ZNF259 and NCAM1. Based on our own
methylation and previously published mutation data,
CADM1 is most likely not inactivated through a two-hit
Knudson mechanism. However, novel concepts in
tumour suppressor genetics such as haploinsufficiency
currently challenge the two-hit paradigm and are gaining
importance in cancer genetics. Hence, an intriguing possi-
bility is sensitivity of CADM1 to gene dosage. In this
respect, the observed reduced expression of CADM1 in
unfavourable NB as compared to normal neuroblasts is
interesting. CADM1 belongs to the family of immu-
noglobulin cell adhesion molecules and encodes a trans-Page 5 of 9
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As disruption or altering of cell-cell interactions is an
important feature of tumour invasion and metastasis, it
could therefore be hypothesised that one working
CADM1 allele is insufficient to accomplish the normal
gene function. This would make NB cells more aggressive
and amenable for migration, invasion and metastasis for-
mation. Furthermore, although the biological cascade of
the CADM1 protein is not yet elucidated, it is interesting
to note that EPB41L3 – an established binding partner of
CADM1 [57] – has been described as higher expressed in
mass screening NB tumours versus aggressive NB [58] and
favourable NB versus unfavourable NB [21]. In 4/5 data
sets, for which expression data on CADM1 and EPB41L3
were available, also a significant positive correlation
between CADM1 and EPB41L3 mRNA expression was
found (p < 0.05). Further research should therefore be
performed to elucidate the involvement of CADM1 in NB.
Conclusion
Tumorigenesis is a multistep process characterised by a
multitude of genetic and epigenetic alterations. In view of
the limited success of classical genomic approaches
towards the identification of NB tumour suppressor
genes, we integrated high resolution array CGH with tran-
scriptome analysis and identified CADM1 as a candidate
11q tumour suppressor gene with prognostic power.
CADM1 does not seem to be inactivated through a two-hit
mechanism in NB. However, due to the frequent involve-
ment of CADM1 in human tumorigenesis and its pre-
sumed role in invasion, a hallmark of malignancy, further
studies should be performed to confirm CADM1 involve-
ment in NB and elucidate its mode of action.
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